Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance

Experimental Dermatology

Volumn 14, Issue 11, 2005, Pages 811-818

  Campioni, Mara ^a   Santini, Daniele ^b   Tonini, Giuseppe ^b   Murace, Raffaele ^c   Dragonetti, Emanuele ^d   Spugnini, Enrico P ^e   Baldi, Alfonso ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c IML   (Italy)

^d Rome American Hospital   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apaf 1; Apoptosis; Chemoresistance; Melanoma progression

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 9; CYTOCHROME C; PROTEIN PRECURSOR;

APOPTOSIS; CANCER GROWTH; CANCER RESISTANCE; CELL INCLUSION; CLINICAL FEATURE; GENE FUNCTION; GENE STRUCTURE; MELANOMA; MITOCHONDRION; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; PROTEINS; SKIN NEOPLASMS;

EID: 27744591569     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2005.00360.x     Document Type: Review

References (77)

1. Zou H, Henzel W J, Liu X et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997: 90: 405-413.
2. Li P, Nijhawan D, Budihardjo I et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997: 91: 479-489.
3. Hausmann G, O'Reilly L A, van Driel R et al. Proapoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-x (L). J Cell Biol 2000: 149: 623-634.
4. Benedict M A, Hu Y, Inohara N et al. Expression and functional analysis of Apaf-1 isoforms. J Biol Chem 2000: 275: 8461-8468.
5. Lockshin R A, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol 2001: 2: 545-550.
6. Thompson C B. Apoptosis in the pathogenesis and treatment of disease. Science 1995: 267: 1456-1462.
7. Thornberry N A, Lazebnik Y. Caspases: enemies within. Science 1998: 281: 1312-1316.
8. Green D R. Apoptotic pathways: the roads to ruin. Cell 1998: 94: 695-698.
9. Acehan D, Jiang X, Morgan D G et al. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 2002: 9: 423-432.
10. Srinivasula S M, Ahmad M, Fernandes-Alnemri T et al. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998: 1: 949-957.
11. Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 1998: 8: 267-271.
12. Hu Y, Ding L, Spencer D M et al. WD-40 repeat region regulates Apaf-1 self association and procaspase-9 activation. J Biol Chem 1998: 273: 33489-33494.
13. Cain K, Brown D G, Langlais C et al. Caspase activation involves the formation of the aposome, a large (approximately 700 kDa) caspase-activating complex. J Biol Chem 1999: 274: 22686-22692.
14. Saleh A, Srinivasula S M, Acharya S et al. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999: 274: 17941-17945.
15. Hu Y, Benedict M A, Ding L et al. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J 1999: 18: 3586-3595.
16. Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev 1999: 13: 3179-3184.
17. Hickman E S, Helin K. The regulation of APAF1 expression during development and tumourigenesis. Apoptosis 2002: 7: 167-171.
18. Luo X, Budihardjo I, Zou H et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998: 94: 481-490.
19. Li H, Zhu H, Xu C J et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998: 94: 491-501.
20. Yang J, Liu X, Bhalla K et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997: 275: 1129-1132.
21. Kluck R M, Bossy-Wetzel E, Green D R et al. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997: 275: 1132-1136.
22. Adams J M, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998: 281: 1322-1326.
23. Oda E, Ohki R, Murasawa H et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000: 288: 1053-1058.
24. O'Connor L, Strasser A, O'Reilly L A et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998: 17: 384-395.
25. Bouillet P, Metcalf D, Huang D C et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999: 286: 1735-17388.
26. Vogelstein B, Lane D, Levine A J. Surfing the p53 network. Nature 2000: 408: 307-310.
27. Salvesen G S, Duckett C S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002: 3: 401-410.
28. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001: 15: 2922-2933.
29. Honarpour N, Gilbert S L, Lahn B T et al. Apaf-1 deficiency and neural tube closure defects are found in fog mice. Proc Natl Acad Sci USA 2001: 98: 9683-9687.
30. Zhao R, Gish K, Murphy M et al. The transcriptional program following p53 activation. Cold Spring Harb Symp Quant Biol 2000: 65: 475-482.
31. Kannan K, Kaminski N, Rechavi G et al. DANN microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 2001: 20: 3449-3455.
32. Robles A I, Bemmels N A, Foraker A B et al. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 2001: 61: 6660-6664.
33. El-Deiry W S, Kern S E, Pietenpol J A et al. Definition of a consensus binding site for p53. Nat Genet 1992: 1: 45-49.
34. Furukawa Y, Nishimura N, Furukawa Y et al. Apaf-1 is a mediator of E2F-1 induced apoptosis. J Biol Chem 2002: 277: 39760-39768.
35. Muller H, Bracken A P, Vernell R et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 2001: 15: 267-285.
36. Vousden K H. p53: death star. Cell 2000: 103: 691-694.
37. Polyak K, Xia Y, Zweier J L et al. A model for p53-induced apoptosis. Nature 1997: 389: 300-305.
38. Coldwell M J, Mitchell S A, Stoneley M et al. Initiation of Apaf-1 translation by internal ribosome entry. Oncogene 2000: 19: 899-905.
39. Mitchell S A, Brown E C, Coldwell M J et al. Protein factor requirements of the Apaf-1 internal ribosome entry segment: roles of polypyrimidine tract binding protein and upstream of N-ras. Mol Cell Biol 2001: 21: 3364-3374.
40. Lauber K, Appel H A, Schlosser S F et al. The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis. J Biol Chem 2001: 276: 29772-29781.
41. Balch C M, Buzaid A C, Soong S J et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001: 19: 3635-3648.
42. Houghton A N, Polsky D. Focus on melanoma. Cancer Cell 2002: 2: 275-278.
43. Nathan F E, Mastrangelo M J. Systemic therapy in melanoma. Semin Surg Oncol 1998: 14: 319-327.
44. Soengas M S, Lowe S W. Apoptosis and melanoma chemoresistance. Oncogene 2003: 22: 3138-3151.
45. Schmitt C A, Lowe S W. Apoptosis and therapy. J Pathol 1999: 187: 127-137.
46. Helmbach H, Rossmann E, Kern M A et al. Drug-resistance in human melanoma. Int J Cancer 2001: 93: 617-622.
47. Baldi A, Lombardi D, Russo P et al. Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 2005: 11: 3175-3183.
48. Baldi A, Santini D, De Luca A et al. cDNA array technology in melanoma: an overview. J Cell Physiol 2003: 196: 219-223.
49. DeRisi J, Penland L, Brown P O et al. Use of cDNA microarray to analyze gene expression patterns in human cancer. Nat Genet 1996: 14: 457-460.
50. Clark E A, Golub T R, Landser E S, Hynes R O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000: 406: 532-535.
51. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profilings. Nature 2000: 406: 536-540.
52. Ziegler A, Jonason A S, Leffell D J et al. Sunburn and p53 in the onset of skin cancer. Nature 1994: 372: 773-776.
53. Gilchrest B A, Eller M S, Geller A C et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999: 340: 1341-1348.
54. Ivanova K, van den Wijngaard R, Gerzer R et al. Nonlesional vitiliginous melanocytes are not characterized by an increased proneness to nitric oxide-induced apoptosis. Exp Dermatol 2005: 14: 445-453.
55. Hussein R M, Haemel A K, Wood G S. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003: 1299: 275-288.
56. Bowen A R, Hanks A N, Allen S M et al. Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 2003: 120: 48-55.
57. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998: 1378: F115-17177.
58. Sharpless N E, De Pinho R A. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999: 9: 22-30.
59. Bennet D C. Hunam melanocyte senescence and melanoma susceptibility genes. Oncogene 2003: 22: 3063-3069.
60. Tas F, Duranyildiz D, Argon A et al. Apoptosis of lymphocytes in peripheral blood of patients with melanoma. Med Oncol 2005: 22: 177-182.
61. Li F, Ambrosini G, Chu E Y et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998: 396: 580-584.
62. Albino A P, Vidal M J, McNutt N S et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994: 4: 35-45.
63. Montano X, Shamsher M, Whitehead P et al. Analysis of p53 in human cutaneous melanoma cell lines. Oncogene 1994: 9: 1455-1459.
64. Ragnarsson-Olding B K, Karsberg S, Platz A et al. Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res 2002: 12: 453-463.
65. Soengas M S, Alarcon R M, Yoshida H et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999: 284: 156-159.
66. Kannan K, Kaminski N, Rechavi G et al. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 2001: 20: 3449-3455.
67. Soengas M S, Capodieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001: 409: 207-211.
68. Bird A P, Wolffe A P. Methylation-induced repression - belts, braces, and chromatin. Cell 1999: 99: 451-454.
69. Baldi A, Santini D, Russo P et al. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 2004: 13: 93-97.
70. Zanon M, Piris A, Bersani I et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004: 64: 7386-7394.
71. Del Bello B, Valentini M A, Mangiavacchi P et al. Role of caspases-3 and - 7 in Apaf-1 proteolytic cleavage and degradation events during cisplatin-induced apoptosis in melanoma cells. Exp Cell Res 2004: 293: 302-310.
72. Dai D L, Martinka M, Bush J A et al. Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 2004: 91: 1089-1095.
73. Fujimoto A, Takeuchi H, Taback B et al. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004: 64: 2245-2250.
74. Mustika R, Budiyanto A, Nishigori C et al. Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res 2005: 18: 59-62.
75. Karjalainen J M, Kellokoski J K, Eskelinen M J et al. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 1998: 16: 3584-3591.
76. Baldi A, Santini D, Battista T et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p-21 in human cutaneous melanoma. J Cell Biochem 2001: 83: 364-372.
77. Andersen Mh, Becker J C, Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005: 4: 399-409.